ANS Biotech is pleased to announce a significant breakthrough in pain management research through our successful collaboration with a major pharmaceutical company. This case study highlights the impact of our ALGOGram™ technology in advancing drug development and optimizing therapeutic outcomes.
Successful Collaboration with Big Pharma
Our partnership with a leading pharmaceutical company has yielded remarkable results. Utilizing ALGOGram™ technology, we detected an unexpected and highly efficacious signal in the visceral pain area for the client’s lead compound, a P2X7 receptor antagonist.
This pivotal discovery has initiated a promising research program to explore visceral pain as a secondary indication for the drug. This strategic pathway not only helps in repositioning the drug but also de-risks the development process.
Promising Research Program Initiated
The discovery facilitated by ALGOGram™ has opened new avenues for research and development. By identifying potential secondary applications for existing drug candidates, we significantly enhance their commercial value and clinical impact. This case study underscores the critical role of ALGOGram™ in enabling precise and informed decision-making, thereby streamlining the drug development pipeline for improved outcomes.
Maximizing R&D Success with ALGOGram™
ALGOGram™ is a key asset for accelerating research and development and maximizing the success of your pipeline. This robust in vivo screening tool provides a comprehensive pharmacological profile across five critical pain areas using 10 validated pain models. Our unique analgesic fingerprint aids in fast-tracking decision-making by pinpointing efficacy and assessing behavioral toxicity.
Proven Track Record of Success
With almost 400 compounds successfully profiled and results available in just three weeks, ALGOGram™ stands out as a reliable and rapid solution for enhancing R&D outcomes. Our technology has consistently demonstrated its capability to deliver rapid, reliable results, driving innovation and success in pain management research.
